{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:53:11Z","timestamp":1790221991884,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study synthesizes previous studies to investigate the risk of second primary cancer (SPC) in patients with renal cell carcinoma (RCC) compared with the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following the PRISMA guidelines, four databases were searched for relevant articles without date limits. Studies were included if they reported the standardized incidence ratio (SIR) for SPCs in patients with RCC compared with the general population. Random-effects model employing the Der Simonian and Laird method was used to pool the SIR by SPC sites. Effect heterogeneity was assessed using\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven retrospective cohort studies published between 1993 and 2024 were included in the study. The overall risk of developing any SPCs was higher among RCC patients (pooled SIR\u2009=\u20091.32, CI 1.19\u20131.48). The risk of several SPCs was significantly higher in patients with RCC compared with the general population, including cancers of the contralateral kidney (3.68, CI 1.85\u20137.24), thyroid (3.05, CI 2.57\u20133.62), urinary bladder (2.15, CI 1.40\u20133.30), small intestine (1.98, CI 1.01\u20133.91), leukemia (1.86, CI 1.28\u20132.70), pancreas (1.64, CI 1.22\u20132.19), NH lymphoma (1.55, CI 1.21\u20131.98), melanoma (1.47, CI 1.15\u20131.88), prostate (1.44, CI 1.21\u20131.71), and colorectal (1.25, CI 1.10\u20131.43), bone (2.31, CI 1.25\u20134.27), endocrine system (4.33, CI 3.28\u20135.74) and brain\/nervous system (2.20, CI 1.25\u20133.88).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with RCC have an increased risk of SPCs compared with the general population. These findings highlight the need to develop strategies for the management of SPCs in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-025-04794-7","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:50:35Z","timestamp":1758174635000},"page":"1161-1180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of developing a second primary cancer following a renal cell carcinoma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1243-0564","authenticated-orcid":false,"given":"Samuel","family":"Tundealao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praise","family":"Okunlola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope","family":"Titiloye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolatito","family":"Mayungbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun","family":"Adegbesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Sajja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olajumoke","family":"Olarewaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"4794_CR1","unstructured":"International Agency for Research on Cancer: Global Cancer Observatory: Cancer Today (2022) https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/tables?mode=population&types=0. Accessed 10 July 2025"},{"key":"4794_CR2","unstructured":"Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M (2022) Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol 39(3):2022-vol3. https:\/\/giornaleitalianodinefrologia.it\/wp-content\/uploads\/sites\/3\/2022\/05\/39-03-2022-03.pdf"},{"issue":"1","key":"4794_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E et al (2018) The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 23(1):313\u201326.e5. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.075","journal-title":"Cell Rep"},{"issue":"1","key":"4794_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4794_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00008469-200508000-00002","volume":"14","author":"(IACR, IARC, ENCR) WG","year":"2005","unstructured":"(IACR, IARC, ENCR) WG (2005) International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev 14(4):307\u2013308. https:\/\/doi.org\/10.1097\/00008469-200508000-00002","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"4794_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/COC.0b013e3182438ddf","volume":"36","author":"S Chakraborty","year":"2013","unstructured":"Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ (2013) Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol 36(2):132\u2013142. https:\/\/doi.org\/10.1097\/COC.0b013e3182438ddf","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"4794_CR7","doi-asserted-by":"publisher","first-page":"e7237","DOI":"10.1002\/cam4.7237","volume":"13","author":"MB Bengtsen","year":"2024","unstructured":"Bengtsen MB, Farkas DK, S\u00f8rensen HT, N\u00f8rgaard M (2024) Renal cell carcinoma and risk of second primary cancer: a Danish nationwide cohort study. Cancer Med 13(11):e7237. https:\/\/doi.org\/10.1002\/cam4.7237","journal-title":"Cancer Med"},{"issue":"1","key":"4794_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12967-025-06151-9","volume":"23","author":"M Zeng","year":"2025","unstructured":"Zeng M, Lin A, Jiang A, Qiu Z, Zhang H, Chen S et al (2025) Decoding the mechanisms behind second primary cancers. J Transl Med 23(1):115. https:\/\/doi.org\/10.1186\/s12967-025-06151-9","journal-title":"J Transl Med"},{"issue":"12","key":"4794_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ejca.2014.05.003","volume":"50","author":"T Chen","year":"2014","unstructured":"Chen T, Fallah M, Sundquist K, Liu H, Hemminki K (2014) Risk of subsequent cancers in renal cell carcinoma survivors with a family history. Eur J Cancer 50(12):2108\u20132118. https:\/\/doi.org\/10.1016\/j.ejca.2014.05.003","journal-title":"Eur J Cancer"},{"issue":"12","key":"4794_CR10","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00345-016-1832-4","volume":"34","author":"KS Murray","year":"2016","unstructured":"Murray KS, Zabor EC, Spaliviero M, Russo P, Bazzi WM, Musser JE et al (2016) Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution. World J Urol 34(12):1667\u20131672. https:\/\/doi.org\/10.1007\/s00345-016-1832-4","journal-title":"World J Urol"},{"key":"4794_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.euros.2020.12.007","volume":"24","author":"G Zheng","year":"2021","unstructured":"Zheng G, Sundquist K, Sundquist J, Chen T, F\u00f6rsti A, Hemminki O et al (2021) Second primary cancers after kidney cancers, and kidney cancers as second primary cancers. Eur Urol Open Sci 24:52\u201359. https:\/\/doi.org\/10.1016\/j.euros.2020.12.007","journal-title":"Eur Urol Open Sci"},{"issue":"527","key":"4794_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/01621459.2018.1469994","volume":"114","author":"P Rubin-Delanchy","year":"2019","unstructured":"Rubin-Delanchy P, Heard NA, Lawson DJ (2019) Meta-analysis of mid-p-values: some new results based on the convex order. J Am Stat Assoc 114(527):1105\u20131112. https:\/\/doi.org\/10.1080\/01621459.2018.1469994","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"4794_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R Dersimonian","year":"1986","unstructured":"Dersimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"3","key":"4794_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jrsm.1547","volume":"13","author":"CB Migliavaca","year":"2022","unstructured":"Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z et al (2022) Meta-analysis of prevalence: I2 statistic and how to deal with heterogeneity. Res Synth Methods 13(3):363\u2013367. https:\/\/doi.org\/10.1002\/jrsm.1547","journal-title":"Res Synth Methods"},{"issue":"7109","key":"4794_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"3","key":"4794_CR16","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0022-5347(01)63708-X","volume":"159","author":"CM Anderson","year":"1998","unstructured":"Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA (1998) Coincident renal cell carcinoma and nonHodgkin\u2019s lymphoma: the M. D. Anderson experience and review of the literature. J Urol 159(3):714\u2013717","journal-title":"J Urol"},{"issue":"1","key":"4794_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1464-410X.2005.05880.x","volume":"97","author":"DA Barocas","year":"2006","unstructured":"Barocas DA, Rabbani F, Scherr DS, Vaughan ED Jr (2006) A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int 97(1):33\u201336. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05880.x","journal-title":"BJU Int"},{"issue":"4","key":"4794_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1464-410X.2006.06004.x","volume":"97","author":"C Beisland","year":"2006","unstructured":"Beisland C, Talleraas O, Bakke A, Norstein J (2006) Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int 97(4):698\u2013702. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06004.x","journal-title":"BJU Int"},{"issue":"1","key":"4794_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ijc.32101","volume":"145","author":"EA Boakye","year":"2019","unstructured":"Boakye EA, Buchanan P, Hinyard L, Osazuwa-Peters N, Simpson MC, Schootman M et al (2019) Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. Int J Cancer 145(1):143\u2013153. https:\/\/doi.org\/10.1002\/ijc.32101","journal-title":"Int J Cancer"},{"issue":"1","key":"4794_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2016.05.034","volume":"379","author":"T Chen","year":"2016","unstructured":"Chen T, Kharazmi E, Lou J, Zhang X, Sundquist K, Hemminki K (2016) Risk of second primary cancers after malignant mesothelioma and vice versa. Cancer Lett 379(1):94\u201399. https:\/\/doi.org\/10.1016\/j.canlet.2016.05.034","journal-title":"Cancer Lett"},{"key":"4794_CR21","doi-asserted-by":"publisher","first-page":"e48380","DOI":"10.2196\/48380","volume":"10","author":"YY Choi","year":"2024","unstructured":"Choi YY, Lee M, Kim EH, Lee JE, Jung I, Cheong JH (2024) Risk of subsequent primary cancers among adult-onset 5-year cancer survivors in South Korea: retrospective cohort study. JMIR Public Health Surveill 10:e48380. https:\/\/doi.org\/10.2196\/48380","journal-title":"JMIR Public Health Surveill"},{"issue":"18","key":"4794_CR22","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0959-8049(01)00314-8","volume":"37","author":"E Crocetti","year":"2001","unstructured":"Crocetti E, Buiatti E, Falini P, Gafa L, Tumino R, Falcini F et al (2001) Multiple primary cancer incidence in Italy. Eur J Cancer 37(18):2449\u20132456. https:\/\/doi.org\/10.1016\/S0959-8049(01)00314-8","journal-title":"Eur J Cancer"},{"issue":"19","key":"4794_CR23","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1002\/cam4.4193","volume":"10","author":"E Crocetti","year":"2021","unstructured":"Crocetti E, Mattioli V, Buzzoni C, Franceschi S, Serraino D, Vaccarella S et al (2021) Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998\u20132012. Cancer Med 10(19):6855\u20136867. https:\/\/doi.org\/10.1002\/cam4.4193","journal-title":"Cancer Med"},{"issue":"5","key":"4794_CR24","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1046\/j.1523-1755.2002.00304.x","volume":"61","author":"K Czene","year":"2002","unstructured":"Czene K, Hemminki K (2002) Kidney cancer in the Swedish Family Cancer Database: familial risks and second primary malignancies. Kidney Int 61(5):1806\u20131813. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00304.x","journal-title":"Kidney Int"},{"key":"4794_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canep.2017.10.004","volume":"51","author":"J J\u00e9gu","year":"2017","unstructured":"J\u00e9gu J, Moitry M, Bara S, Tr\u00e9tarre B, Guizard AV, Woronoff AS et al (2017) Methodological issues of assessing the risk of a second cancer occurring in the same site as a first cancer using registry data. Cancer Epidemiol 51:41\u201343. https:\/\/doi.org\/10.1016\/j.canep.2017.10.004","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"4794_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4143\/crt.2016.543","volume":"50","author":"JY Joung","year":"2018","unstructured":"Joung JY, Kwon WA, Lim J, Oh CM, Jung KW, Kim SH et al (2018) Second primary cancer risk among kidney cancer patients in Korea: a population-based cohort study. Cancer Res Treat 50(1):293\u2013301. https:\/\/doi.org\/10.4143\/crt.2016.543","journal-title":"Cancer Res Treat"},{"issue":"2","key":"4794_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MPA.0000000000001232","volume":"48","author":"GR Kamath","year":"2019","unstructured":"Kamath GR, Kim MK, Taioli E (2019) Risk of primary neuroendocrine pancreatic tumor after a first primary cancer a US population-based study. Pancreas 48(2):161\u2013168. https:\/\/doi.org\/10.1097\/MPA.0000000000001232","journal-title":"Pancreas"},{"issue":"4","key":"4794_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.14701\/ahbps.23-053","volume":"27","author":"MJ Kang","year":"2023","unstructured":"Kang MJ, Lim J, Han SS, Park HM, Cho SC, Park SJ et al (2023) Exocrine pancreatic cancer as a second primary malignancy: a population-based study. Ann Hepatobiliary Pancreat Surg 27(4):415\u2013422. https:\/\/doi.org\/10.14701\/ahbps.23-053","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"4794_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canep.2018.10.003","volume":"57","author":"K Kim","year":"2018","unstructured":"Kim K, Chung TH, Etzel CJ, Kim J, Ryu H, Kim DW et al (2018) Association between melanoma and renal-cell carcinoma for sequential diagnoses: a single-center retrospective study. Cancer Epidemiol 57:80\u201384. https:\/\/doi.org\/10.1016\/j.canep.2018.10.003","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"4794_CR30","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1245\/s10434-011-2193-2","volume":"19","author":"G Lal","year":"2012","unstructured":"Lal G, Groff M, Howe JR, Weigel RJ, Sugg SL, Lynch CF (2012) Risk of subsequent primary thyroid cancer after another malignancy: latency trends in a population-based study. Ann Surg Oncol 19(6):1887\u20131896. https:\/\/doi.org\/10.1245\/s10434-011-2193-2","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4794_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/bjc.1993.72","volume":"67","author":"F Levi","year":"1993","unstructured":"Levi F, Randimbison L, Te VC, Rolland-Portal I, Franceschi S, La Vecchia C (1993) Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974\u201389. Br J Cancer 67(2):391\u2013395. https:\/\/doi.org\/10.1038\/bjc.1993.72","journal-title":"Br J Cancer"},{"issue":"1","key":"4794_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12885-017-3683-9","volume":"17","author":"O Preyer","year":"2017","unstructured":"Preyer O, Concin N, Obermair A, Concin H, Ulmer H, Oberaigner W (2017) The relative risk of second primary cancers in Austria\u2019s western states: a retrospective cohort study. BMC Cancer 17(1):699. https:\/\/doi.org\/10.1186\/s12885-017-3683-9","journal-title":"BMC Cancer"},{"issue":"1","key":"4794_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ijc.22159","volume":"120","author":"G Sc\u00e9lo","year":"2007","unstructured":"Sc\u00e9lo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH et al (2007) Associations between ocular melanoma and other primary cancers: an international population-based study. Int J Cancer 120(1):152\u2013159. https:\/\/doi.org\/10.1002\/ijc.22159","journal-title":"Int J Cancer"},{"issue":"1","key":"4794_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ijc.21284","volume":"118","author":"G Sc\u00e9lo","year":"2006","unstructured":"Sc\u00e9lo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Andersen A et al (2006) Associations between small intestine cancer and other primary cancers: an international population-based study. Int J Cancer 118(1):189\u2013196. https:\/\/doi.org\/10.1002\/ijc.21284","journal-title":"Int J Cancer"},{"key":"4794_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.101664","author":"SJ Schonfeld","year":"2020","unstructured":"Schonfeld SJ, Morton LM, de Gonz\u00e1lez AB, Curtis RE, Kitahara CM (2020) Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000\u20132015. Cancer Epidemiol. https:\/\/doi.org\/10.1016\/j.canep.2019.101664","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"4794_CR36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1349-7006.2012.02254.x","volume":"103","author":"T Tabuchi","year":"2012","unstructured":"Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H (2012) Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. Cancer Sci 103(6):1111\u20131120. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02254.x","journal-title":"Cancer Sci"},{"key":"4794_CR37","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-2059","author":"X Zheng","year":"2020","unstructured":"Zheng X, Li X, Wang M, Shen J, Sisti G, He Z et al (2020) Second primary malignancies among cancer patients. Ann Transl Med. https:\/\/doi.org\/10.21037\/atm-20-2059","journal-title":"Ann Transl Med"},{"issue":"2","key":"4794_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.15586\/jkcvhl.v11i2.309","volume":"11","author":"N Beecroft","year":"2024","unstructured":"Beecroft N, Gauntner TD, Upadhyay R, Wang S-J, Yang Y, Singer EA et al (2024) Active surveillance in metastatic renal cell carcinoma. J Kidney Cancer VHL 11(2):27\u201338. https:\/\/doi.org\/10.15586\/jkcvhl.v11i2.309","journal-title":"J Kidney Cancer VHL"},{"issue":"5","key":"4794_CR39","doi-asserted-by":"publisher","first-page":"237.e11","DOI":"10.1016\/j.urolonc.2015.11.017","volume":"34","author":"EH Kim","year":"2016","unstructured":"Kim EH, Vetter JM, Kuxhausen AN, Song JB, Sandhu GS, Strope SA (2016) Limited use of surveillance imaging following nephrectomy for renal cell carcinoma. Urol Oncol Semin Orig Investig 34(5):237.e11-237.e18. https:\/\/doi.org\/10.1016\/j.urolonc.2015.11.017. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1078143915005694?via%3Dihub","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"6","key":"4794_CR40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/oxfordjournals.aje.a117689","volume":"142","author":"CB Begg","year":"1995","unstructured":"Begg CB, Zhang Z-F, Sun M, Herr HW, Schantz SP (1995) Methodology for evaluating the incidence of second primary cancers with application to smoking-relted cancers from the Surveillance, Epidmiology, and End Results (SEER) program. Am J Epidemiol 142(6):653\u2013665. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a117689","journal-title":"Am J Epidemiol"},{"issue":"5","key":"4794_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrurol.2010.46","volume":"7","author":"W-H Chow","year":"2010","unstructured":"Chow W-H, Dong LM, Devesa SS (2010) Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7(5):245\u2013257. https:\/\/doi.org\/10.1038\/nrurol.2010.46","journal-title":"Nat Rev Urol"},{"key":"4794_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45014-4","author":"A Seretis","year":"2019","unstructured":"Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez DS, Ntzani EE et al (2019) Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-45014-4","journal-title":"Sci Rep"},{"issue":"3","key":"4794_CR43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/jco.2000.18.3.498","volume":"18","author":"AJ Swerdlow","year":"2000","unstructured":"Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW et al (2000) Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18(3):498. https:\/\/doi.org\/10.1200\/jco.2000.18.3.498","journal-title":"J Clin Oncol"},{"issue":"6","key":"4794_CR44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrurol.2010.57","volume":"7","author":"M Sun","year":"2010","unstructured":"Sun M, Lughezzani G, Perrotte P, Karakiewicz PI (2010) Treatment of metastatic renal cell carcinoma. Nat Rev Urol 7(6):327\u2013338. https:\/\/doi.org\/10.1038\/nrurol.2010.57","journal-title":"Nat Rev Urol"},{"issue":"12","key":"4794_CR45","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1089\/thy.2007.0171","volume":"17","author":"S Subramanian","year":"2007","unstructured":"Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I et al (2007) Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17(12):1277\u20131288. https:\/\/doi.org\/10.1089\/thy.2007.0171","journal-title":"Thyroid"},{"issue":"11","key":"4794_CR46","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/jco.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE et al (2024) Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 42(11):1222\u20131228. https:\/\/doi.org\/10.1200\/jco.23.01569","journal-title":"J Clin Oncol"},{"issue":"3","key":"4794_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00384-022-04105-x","volume":"37","author":"D Robertson","year":"2022","unstructured":"Robertson D, Ng SK, Baade PD, Lam AK (2022) Risk of extracolonic second primary cancers following a primary colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 37(3):541\u2013551. https:\/\/doi.org\/10.1007\/s00384-022-04105-x","journal-title":"Int J Colorectal Dis"},{"issue":"3","key":"4794_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.radonc.2016.08.017","volume":"121","author":"T Grantzau","year":"2016","unstructured":"Grantzau T, Overgaard J (2016) Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol 121(3):402\u2013413. https:\/\/doi.org\/10.1016\/j.radonc.2016.08.017","journal-title":"Radiother Oncol"},{"issue":"2","key":"4794_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41416-018-0273-9","volume":"120","author":"DC Gilbert","year":"2019","unstructured":"Gilbert DC, Wakeham K, Langley RE, Vale CL (2019) Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. Br J Cancer 120(2):256\u2013268. https:\/\/doi.org\/10.1038\/s41416-018-0273-9","journal-title":"Br J Cancer"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04794-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:37:49Z","timestamp":1773844669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04794-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4794"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04794-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This systematic review and meta-analysis was not subject to an institutional board review. The study\u2019s protocol was, however, preregistered in PROSPERO (CRD420251072650).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}